Navigation Links
Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Date:5/19/2011

AP, which affects more than 10,000 patients worldwide.  Patients with FAC have TTR build up in the heart muscle and succumb to heart failure five to six years after symptom onset.  Patients with FAP have TTR build up in peripheral nerve tissue leading to the loss of nerve function and wasting.  ISIS-TTRRx inhibits the production of all forms of TTR, offering a unique approach to treat all types of transthyretin-related amyloidosis.  

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' collaboration with GlaxoSmithKline, the discovery, development and potential of drugs for severe and rare diseases, and the dev
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
4. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
9. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
10. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
11. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... Due to a misstatement posted by the Family ... Technology Center, LLC ( ASCTC ) was reported as an ... might benefit ALS patients. Because of ASCTC's exclusive focus ... and therapeutic applications, FRC listed ASCTC as one of several ... wish not to support research that requires the death of ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
(Date:8/28/2014)... City, CA (PRWEB) August 28, 2014 ... sanitation products for the food processing industry, is asking ... a side-by side comparison of the E2 soap they’re ... E2 Sanitizing Foam Soap . Hand hygiene is ... in the food processing environment. Six key criteria are ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... the most active legislative periods from the standpoint of technology ... the state has no more excuses when it comes to ... , R-Brookfield, stopped short of saying all the legislature's technology ... liability, and IT tax credit bills, he said the major ...
... Milwaukee, Wis. - Brian Hurdis is wrestling ... bit as high as they are for most business ... vice president and chief information officer for Metavante ... that will be rolled across all of the company's ...
... Wis. - Dr. Lou Tornatzky, co-author of a white ... economy, said the city has all the pieces in place ... present his ideas here during a July 10 luncheon program ... even more in place than did some of the nation's ...
Cached Biology Technology:Kanavas says Wisconsin has no more excuses 2Kanavas says Wisconsin has no more excuses 3Kanavas says Wisconsin has no more excuses 4CIO Leadership Series: Brian Hurdis, Metavante 2CIO Leadership Series: Brian Hurdis, Metavante 3CIO Leadership Series: Brian Hurdis, Metavante 4Innovation expert says Milwaukee has all the tools 2Innovation expert says Milwaukee has all the tools 3Innovation expert says Milwaukee has all the tools 4
(Date:8/29/2014)... as the prolific bloomer Emiliania huxleyi , can ... The finding contradicts the common view that E. ... scarce supplies of thiamine in the ocean to survive. ... the ocean," says CIFAR Senior Fellow Alexandra Worden ... with CIFAR fellows John Archibald (Dalhousie University), ...
(Date:8/28/2014)... app called TX Invasives is now available from the ... Texas at Austin for identifying harmful non-native plant, insect ... in the United States cause about $137 billion in ... crops, clog waterways, kill native plants and more. , ... for reporting where invasive species occur, we,re more likely ...
(Date:8/28/2014)... available in German . ... its name to a striking pattern of blue stripes alternating ... reflective silvery cells, and yellow cells emerge during growth in ... a multilayered mosaic to compose the characteristic colour pattern. ... have to interact to form proper stripes, the embryonic origin ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Mobile app makes ID of harmful plants, insects in Texas a snap 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... but they often require a lot of work to thrive. ... about the environment and reluctant to use pesticides. W. ... several varieties of roses to determine which grow best with ... the American Society for Horticultural Science journal HortTechnology . ...
... Platelets, tiny and relatively uncharted tenants of the ... clotting, turn out to also rally sustained immune ... in organ transplant rejection, according to a new ... hold sway over many aspects of transplant biology," ...
... have been linked to bait use of horseshoe crabs. ... of red knots when they leave Delaware Bay has declined ... has been reduced. The study also revealed that red knot ... size of red knots has declined by more than 75 ...
Cached Biology News:Researchers explore new driver of transplant rejection: Platelets 2Researchers explore new driver of transplant rejection: Platelets 3Decline of shorebird linked to bait use of horseshoe crabs 2
... complete components including positive and negative control ... in cultured cells and tissue sections. The ... greater sensitivity than biotinylated or digoxigenylated methods. ... The kit works well with GFP transfected ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... ion chromatography system . The sensitive conductivity ... to 5000S, houses the measuring cell in a ... is available. Data processing is provided by ... is by the high pressure CE 4100 dual ...
The Mu-End™ Protein Truncation Kit provides a convenient method for generating a library of N-terminal and C-terminal protein deletions that can be expressed in E. coli....
Biology Products: